Repligen Co. (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Analysts

Repligen Co. (NASDAQ:RGEN) has received an average recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and ten have issued a buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $189.55.

A number of equities research analysts recently weighed in on RGEN shares. UBS Group lowered their price objective on shares of Repligen from $210.00 to $170.00 and set a “buy” rating for the company in a research report on Thursday, November 2nd. Stephens boosted their price objective on shares of Repligen from $180.00 to $200.00 and gave the company an “overweight” rating in a research report on Thursday, August 3rd. Stifel Nicolaus lowered their price objective on shares of Repligen from $200.00 to $165.00 and set a “buy” rating for the company in a research report on Wednesday, November 1st. KeyCorp decreased their target price on shares of Repligen from $240.00 to $210.00 and set an “overweight” rating for the company in a research report on Wednesday, November 1st. Finally, StockNews.com started coverage on shares of Repligen in a research report on Thursday, October 5th. They issued a “sell” rating for the company.

Repligen Stock Performance

Shares of Repligen stock opened at $155.64 on Tuesday. The firm has a market cap of $8.69 billion, a PE ratio of 76.67, a price-to-earnings-growth ratio of 3.67 and a beta of 1.06. The firm’s 50-day simple moving average is $150.11 and its 200-day simple moving average is $157.50. Repligen has a 1 year low of $110.45 and a 1 year high of $200.98.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported $0.23 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.09. Repligen had a net margin of 17.29% and a return on equity of 6.08%. The business had revenue of $141.20 million during the quarter, compared to the consensus estimate of $140.68 million. During the same quarter in the prior year, the firm earned $0.77 EPS. The company’s revenue for the quarter was down 29.6% compared to the same quarter last year. On average, equities analysts predict that Repligen will post 1.72 earnings per share for the current year.

Insider Activity

In other news, insider Christine Gebski sold 3,788 shares of the stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $147.13, for a total value of $557,328.44. Following the completion of the transaction, the insider now directly owns 28,787 shares in the company, valued at $4,235,431.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Christine Gebski sold 3,788 shares of the stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $147.13, for a total value of $557,328.44. Following the completion of the transaction, the insider now directly owns 28,787 shares in the company, valued at $4,235,431.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Karen A. Dawes sold 850 shares of the stock in a transaction that occurred on Tuesday, August 29th. The shares were sold at an average price of $171.38, for a total transaction of $145,673.00. Following the sale, the director now directly owns 83,741 shares of the company’s stock, valued at $14,351,532.58. The disclosure for this sale can be found here. Insiders own 1.10% of the company’s stock.

Institutional Trading of Repligen

Several institutional investors and hedge funds have recently added to or reduced their stakes in RGEN. Wellington Management Group LLP lifted its stake in Repligen by 79.8% during the first quarter. Wellington Management Group LLP now owns 1,493,551 shares of the biotechnology company’s stock valued at $251,454,000 after purchasing an additional 662,807 shares during the last quarter. Parnassus Investments LLC purchased a new stake in shares of Repligen in the 3rd quarter valued at approximately $87,475,000. Perpetual Ltd purchased a new stake in shares of Repligen in the 1st quarter valued at approximately $80,212,000. Norges Bank purchased a new stake in shares of Repligen in the 4th quarter valued at approximately $76,155,000. Finally, Alyeska Investment Group L.P. purchased a new stake in shares of Repligen in the 1st quarter valued at approximately $67,008,000. 97.64% of the stock is owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.